Literature DB >> 19160243

Short versus standard duration antibiotic therapy for acute streptococcal pharyngitis in children.

Saleh Altamimi1, Adli Khalil, Khalid A Khalaiwi, Ruth Milner, Martin V Pusic, Mohammed A Al Othman.   

Abstract

BACKGROUND: The standard duration of treatment for acute group A beta hemolytic streptococcus (GABHS) pharyngitis with oral penicillin is 10 days. Shorter duration antibiotics may have comparable efficacy.
OBJECTIVES: To summarize the evidence regarding the efficacy of two to six days of newer oral antibiotics (short duration) compared to 10 days of oral penicillin (standard duration) in treating children with acute GABHS pharyngitis. SEARCH STRATEGY: We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library 2007, issue 4), which contains the Acute Respiratory Infections Group's Specialized Register; the Database of Abstracts of Reviews of Effects (DARE); MEDLINE (1966 to October 2007); OLDMEDLINE (1950 to December 1965); and EMBASE (January 1990 to November 2007). SELECTION CRITERIA: Randomized controlled trials (RCTs) comparing short duration oral antibiotics to standard duration oral penicillin in children aged 1 to 18 years with acute GABHS pharyngitis. DATA COLLECTION AND ANALYSIS: Two review authors scanned the titles and abstracts of retrieved citations and applied the inclusion criteria. We retrieved included studies in full and extracted data. Two review authors independently assessed trial quality. MAIN
RESULTS: Twenty studies were included with 13,102 cases of acute GABHS pharyngitis. Compared to standard duration treatment, the short duration treatment had shorter periods of fever (mean difference (MD) -0.30 days, 95% CI -0.45 to -0.14) and throat soreness (MD -0.50 days, 95% CI -0.78 to -0.22); lower risk of early clinical treatment failure (OR 0.80, 95% CI 0.67 to 0.94); no significant difference in early bacteriological treatment failure (OR 1.08, 95% CI 0.97 to 1.20), or late clinical recurrence (OR 0.95, 95% CI 0.83 to 1.08). However, the overall risk of late bacteriological recurrence was worse in the short duration treatment (OR 1.31, 95% CI 1.16 to 1.48), although no significant differences were found when studies of low dose azithromycin (10mg/kg) were eliminated (OR 1.06, 95% CI 0.92 to 1.22). Three studies reported long duration complications with no statistically significant difference (OR 0.53, 95% CI 0.17 to 1.64). AUTHORS'
CONCLUSIONS: Three to six days of oral antibiotics had comparable efficacy compared to the standard duration 10 day oral penicillin in treating children with acute GABHS pharyngitis. In countries with low rates of rheumatic fever, it appears safe and efficacious to treat children with acute GABHS pharyngitis with short duration antibiotics. In areas where the prevalence of rheumatic heart disease is still high, our results must be interpreted with caution.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19160243     DOI: 10.1002/14651858.CD004872.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  11 in total

1.  Streptococcal pharyngitis - time to move beyond penicillins?

Authors:  Joan L Robinson
Journal:  Paediatr Child Health       Date:  2010-12       Impact factor: 2.253

2.  Treatment of streptococcal pharyngitis with once-daily amoxicillin versus intramuscular benzathine penicillin G in low-resource settings: a randomized controlled trial.

Authors:  Anne W Rimoin; Nicole A Hoff; Christa L Fischer Walker; Hala S Hamza; Adriana Vince; Naglaa Abdel Rahman; Sasa Andrasevic; Soha Emam; Dubravka Vukelic; Nevine Elminawi; Hadeer Abdel Ghafar; Antonia L A da Cunha; Shamim Qazi; Dace Gardovska; Mark C Steinhoff
Journal:  Clin Pediatr (Phila)       Date:  2011-02-11       Impact factor: 1.168

Review 3.  Update on the management of acute pharyngitis in children.

Authors:  Marta Regoli; Elena Chiappini; Francesca Bonsignori; Luisa Galli; Maurizio de Martino
Journal:  Ital J Pediatr       Date:  2011-01-31       Impact factor: 2.638

4.  Azithromycin in acute bacterial upper respiratory tract infections: an Indian non-interventional study.

Authors:  Shaantanu Donde; Anupam Mishra; Puja Kochhar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2012-01-07

Review 5.  Rheumatic heart disease: progress and challenges in India.

Authors:  Bela Shah; Meenakshi Sharma; Rajesh Kumar; K N Brahmadathan; Vinod Joseph Abraham; Rajan Tandon
Journal:  Indian J Pediatr       Date:  2012-09-02       Impact factor: 1.967

6.  Influence of the duration of penicillin prescriptions on outcomes for acute sore throat in adults: the DESCARTE prospective cohort study in UK general practice.

Authors:  Michael Moore; Beth Stuart; Fd Richard Hobbs; Chris C Butler; Alastair D Hay; John Campbell; Brendan C Delaney; Sue Broomfield; Paula Barratt; Kerenza Hood; Hazel Everitt; Mark Mullee; Ian Williamson; David Mant; Paul Little
Journal:  Br J Gen Pract       Date:  2017-08-14       Impact factor: 5.386

7.  "Ten Commandments" for the Appropriate use of Antibiotics by the Practicing Physician in an Outpatient Setting.

Authors:  Gabriel Levy-Hara; Carlos F Amábile-Cuevas; Ian Gould; Jim Hutchinson; Lilian Abbo; Lynora Saxynger; Erika Vlieghe; Fernando L Lopes Cardoso; Shaheen Methar; Souha Kanj; Norio Ohmagari; Stephan Harbarth
Journal:  Front Microbiol       Date:  2011-11-24       Impact factor: 5.640

Review 8.  Tonsillitis and sore throat in children.

Authors:  Klaus Stelter
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2014-12-01

9.  Evaluation of Rational Drug Use for Acute Pharyngitis Associated with the Incidence and Prevalence of the Disease at Two Community Health Centers in Indonesia.

Authors:  Cindra T Yuniar; Kusnandar Anggadiredja; Alfi N Islamiyah
Journal:  Sci Pharm       Date:  2017-04-28

10.  One year results of a randomized controlled clinical study evaluating the effects of non-surgical periodontal therapy of chronic periodontitis in conjunction with three or seven days systemic administration of amoxicillin/metronidazole.

Authors:  Raluca Cosgarea; Christian Heumann; Raluca Juncar; Roxana Tristiu; Liana Lascu; Giovanni E Salvi; Nicole B Arweiler; Anton Sculean
Journal:  PLoS One       Date:  2017-06-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.